
S&P TEST

SWOT & PESTLE.com

NOVAVAX INC. SWOT & PESTLE ANALYSIS

© Barakaat Consulting - An Ezzy IT Consulting Business

This is a licensed product and is not to be photocopied or distributed. All rights reserved. Unauthorized reproduction is strictly prohibited. Research is based on best available materials and resources. To purchase reprints of this document, please email support@swotandpestle.com.

Company Name : Novavax Inc.

Company Sector : Pharmaceutical, Healthcare

Operating Geography : United States, North America, Global

About the Company :

Novavax Inc., is an American biotechnology company headquartered in Gaithersburg, Maryland. Novavax Inc., was initially founded to focus on the development of experimental vaccines and was established in 1987. It promotes improved health globally by discovering and developing innovative vaccines. The company develops and commercializes vaccines which help in preventing serious infectious diseases. Prior to 2020, the company's scientists developed vaccines for diseases such as Ebola, Respiratory Syncytial Virus (RSV), and influenza and later it refocused its efforts and concentrated on developing COVID-19 vaccines in 2020. The firm has thus taken steps for ensuring the continued advancement of its influenza vaccine. It has been honoured with fast-track status in January 2020, by the U.S. Food and Drug Administration (FDA) for NanoFlu. In January 2021, the company announced the results of phase 3 trials that showed 89 percent efficacy against Covid-19. The vaccine also provides high immunity against novel variations, according to the report. Novavax, Inc. announced in April 2022 that the Australian Therapeutic Goods Administration (TGA) had granted provisional registration of the Nuvaxovid™ (NVX-CoV2373) COVID-19 vaccine as a booster in people aged 18 and up.

Novavax Inc.'s Unique Selling Point or USP lies in it being one of the most advanced vaccine development businesses in the world. Recombinant Nanoparticle Vaccine Technology and Matrix-M adjuvant Technology are two of the company's exclusive innovations. Novavax's vision statement reads, "Our vision is a resilient Joint Force enabled to fight and win, unencumbered by a chemical, biological, radiological, or nuclear environment".

Revenue :

US\$ 1.1 billion - FY ending 31st December 2021 (131% y-o-y growth)

US\$ 475.6 million - FY ending 31st December 2020 (2456% y-o-y growth)

US\$ 18.6 million - FY ending 31st December 2019

SWOT Analysis :

The SWOT Analysis for Novavax Inc. is given below:

Strengths	Weaknesses
<ul style="list-style-type: none"> 1.Unique process for vaccine development 2.Diversified medicines for multiple diseases 3.Numerous patents and patent laws keep the company in the forefront 4.Strategic alliances with various bodies to ensure better drug development across the world 	<ul style="list-style-type: none"> 1.Dependence on third party for testing and trials 2.Numerous government regulations increase operational costs for the company 3.FDA approval process takes a long time which limits ability of the company to launch new drugs quickly 4.Uncertainty over funding for the company's COVID vaccine
Opportunities	Threats
<ul style="list-style-type: none"> 1.Covid vaccination drives in USA and other nations will drive revenues for the company 2.Getting involved in vaccination of underdeveloped countries and expanding its vaccine portfolio 	<ul style="list-style-type: none"> 1.Intense competition from other drug manufacturers may affect profits for the company 2.Commercial success of vaccine candidates are uncertain due to uncertainty over prices and reimbursements

PESTLE Analysis :

The PESTLE Analysis for Novavax Inc. is given below:

Political	Economical
1.Impact of Biden administration on the pharmaceutical industry 2.US-China trade war affects the pharmaceutical industry by supply chain disruptions	1.Impact of COVID-19 on pharmaceutical industry in USA
Social	Technological
1.Vaccination drives for COVID and other diseases continue which would generate revenues for drug makers	1.Use of AI and ML in the development of drugs in USA 2.Digitalization of the drug manufacturing process in the pharma sector 3.Developing next-generation flu vaccine for improved protection
Legal	Environmental
1.Pharmaceutical and FDA regulations for new drug development 2.Patent laws and its protection in USA	1.Impact of climate change on US's pharmaceutical industry

Please note that our free summary reports contain the SWOT and PESTLE table contents only.
 The complete report for **Novavax Inc.** SWOT & PESTLE Analysis is a paid report at **15.53 U.S.D.**



* By clicking on "Buy Now" you agree to accept our "Terms and Conditions."



S&P

SWOT & PESTLE.com

SWOT & PESTLE.com is a leading strategy research portal covering detailed Strengths, Weaknesses, Opportunities, Threats (SWOT) and Political, Economic, Social, Technological, Legal and Environmental (PESTLE) analysis of leading industry sectors and organizations across the globe. Our full and comprehensive collection on SWOT and PESTLE has been written by our team of professional analysts consisting of MBA's, CFA's and industry experts. Our analysis has helped businesses, researchers and scholars with valuable insights to make strategic decisions and take their research forward.

We at SWOT & PESTLE.com aim to aid the understanding of the multifaceted business world by presenting a list of diverse companies from across the globe. Business organizations today cannot function in ways that ignore the surroundings that they are set in. SWOT & PESTLE.com makes a keen observation into this aspect and accounts for factors affecting such businesses.

Copyright Notice

The information provided in the SWOT and PESTLE research reports on www.swotandpestle.com are from publicly available documents and sources which are deemed reliable. Further the reports contain analysis and views from the SWOT & PESTLE.com research and analyst team which consists of qualified experts. While every attempt has been made to ensure completeness, accuracy and reliability of the analysis, Barakaat Consulting and its associate websites cannot be held responsible or legal liable for omissions or errors in our reports or on any of our pages.

(C)2024 Barakaat Consulting. All rights reserved. This report may not be reproduced, copied or redistributed, in whole or in part, in any form or by any means, without the express written consent of Barakaat Consulting. Also, Barakaat Consulting is the sole copyright owner of this report, and any use of this report by any third party is strictly prohibited without a license expressly granted by Barakaat Consulting. Neither all nor any part of the contents of this report, or any opinions expressed herein, can be used in advertising, press releases, or promotional materials without prior written approval from Barakaat Consulting. Any violation of Barakaat Consultings rights in this report will be executed to the fullest extent of the law, including the pursuit of monetary damages and injunctive relief in the event of any breach of the foregoing restrictions.

Client Support:
support@swotandpestle.com